Abstract
Alzheimer’s Disease (AD) is the major cause of senile dementia, flawing out 10% of 65 years old population and 50% of 85 years old, globally. The major physiopathology of AD is the deposition of extracellular neuritic plaques in memory related areas of the brain. These plaques are composed of the β-amyloid peptide resulting from the amyloidogenic pathway, that starts with the β-secretase enzyme. BACE-1 (β-secretase 1) is considered one of the most promising treatments of the disease. In this work, different molecular modeling and drug design techniques were used to design novel inhibitors of BACE-1, starting from structures available in the Protein Data Bank. The results obtained from virtual screening of compound libraries lead to 28 promising compounds, which were then evaluated by toxicity prediction, pharmacokinetic properties and analysis of the binding modes in the catalytic site, resulting in 10 compounds with high theoretical inhibition potential.
Keywords: BACE-1, Alzheimer, virtual screening
Current Bioactive Compounds
Title:Structure and Ligand Based Rational Drug Design for Bace-1 Inhibitors
Volume: 9 Issue: 1
Author(s): E. P. Semighini, Carlton A. Taft and C. H. T. P. Silva
Affiliation:
Keywords: BACE-1, Alzheimer, virtual screening
Abstract: Alzheimer’s Disease (AD) is the major cause of senile dementia, flawing out 10% of 65 years old population and 50% of 85 years old, globally. The major physiopathology of AD is the deposition of extracellular neuritic plaques in memory related areas of the brain. These plaques are composed of the β-amyloid peptide resulting from the amyloidogenic pathway, that starts with the β-secretase enzyme. BACE-1 (β-secretase 1) is considered one of the most promising treatments of the disease. In this work, different molecular modeling and drug design techniques were used to design novel inhibitors of BACE-1, starting from structures available in the Protein Data Bank. The results obtained from virtual screening of compound libraries lead to 28 promising compounds, which were then evaluated by toxicity prediction, pharmacokinetic properties and analysis of the binding modes in the catalytic site, resulting in 10 compounds with high theoretical inhibition potential.
Export Options
About this article
Cite this article as:
Semighini E. P., A. Taft Carlton and Silva C. H. T. P., Structure and Ligand Based Rational Drug Design for Bace-1 Inhibitors, Current Bioactive Compounds 2013; 9 (1) . https://dx.doi.org/10.2174/1573407211309010003
DOI https://dx.doi.org/10.2174/1573407211309010003 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer’s Disease
Current Alzheimer Research Molecular Modelling Studies on Thiazole-Based α-Glucosidase Inhibitors Using Docking and CoMFA, CoMSIA and HQSAR
Current Drug Discovery Technologies Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research Drug-Induced Hypothermia in Stroke Models: Does it Always Protect?
CNS & Neurological Disorders - Drug Targets The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
Current Pharmaceutical Design A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism Vitamin-mediated immune regulation in the development of inflammatory diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Molecular Targeting for Development of Novel Therapeutic Strategies in Brain Diseases: Myth or Reality?)
CNS & Neurological Disorders - Drug Targets Disentangling the Intricacies of Migraine: A Review
CNS & Neurological Disorders - Drug Targets Statins And Stroke
Current Medicinal Chemistry Imaging of Muscarinic Receptors in the Central Nervous System
Current Pharmaceutical Design Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers Disease
Current Pharmaceutical Design Vitamin D and Vitamin D Receptor Activators in Treatment of Hypertension and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Anti-Copper Therapies in Alzheimers Disease: New Concepts
Recent Patents on CNS Drug Discovery (Discontinued) Molecular Hydrogen Application in Stroke: Bench to Bedside
Current Pharmaceutical Design